The Medical Oncologist’s Point of View

  • Massimo Lopez
  • Laura Giacinti
  • Silvia I.S. Fattoruso
Part of the Updates in Surgery book series (UPDATESSURG)


In the treatment of cancer, one of the basic assumptions is that all malignant cells should be removed or destroyed to achieve cure. To do this, surgery and/or radiotherapy have been traditionally the primary chosen treatments in solid tumors. However, neither modality can be considered curative once disease is beyond the local region, and clinical evidence has already shown that surgical removal or radiotherapeutic ablation of “localized” masses do not achieve the desired cancer control in a large number of patients. In fact, many tumors which are apparently localized are already microscopically disseminated.


Gastric Cancer Overall Survival Pancreatic Cancer Clin Oncol Embryonal Rhabdomyosarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Niederhuber JE (2004) Surgical intervention in cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (eds) Clinical Oncology, 3rd edn. Elsevier, Philadelphia, pp 579–590Google Scholar
  2. 2.
    Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRefGoogle Scholar
  3. 3.
    Saltz LB, Niedzwiecki D, Hollis D et al (2004) Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol 22:246sGoogle Scholar
  4. 4.
    Van Cutsem E, Labianca R, Hossfeld G et al (2005) Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (PETACC 3). J Clin Oncol 23:3sGoogle Scholar
  5. 5.
    Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351PubMedCrossRefGoogle Scholar
  6. 6.
    De Gramont A, Boni C, Navarro M et al (2005) Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Proc Am Soc Clin Oncol 23:246sGoogle Scholar
  7. 7.
    Wolmark N, Wieand HS, Keubler JP et al (2005) A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07. J Clin Oncol 23:16sGoogle Scholar
  8. 8.
    Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704PubMedCrossRefGoogle Scholar
  9. 9.
    Schmoll H, Tabernero J, Nowacki M et al (2005) Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients with stage III colon cancer. J Clin Oncol 23:16sGoogle Scholar
  10. 10.
    Benson AB III, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419PubMedCrossRefGoogle Scholar
  11. 11.
    Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemora-diotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRefGoogle Scholar
  12. 12.
    Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487PubMedCrossRefGoogle Scholar
  13. 13.
    Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMedGoogle Scholar
  14. 14.
    Modern multimodality approach to hepatic colorectal metastases: solutions and controversies (2007) Surg Oncol 16:71–83Google Scholar
  15. 15.
    Benoist S, Brouquet A, Penna C (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939–3945PubMedCrossRefGoogle Scholar
  16. 16.
    Zhao SL, Fang JY (2008) The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest 26:317–325PubMedCrossRefGoogle Scholar
  17. 17.
    Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRefGoogle Scholar
  18. 18.
    Wagner AD, Grothe W, Haerting J, et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909PubMedCrossRefGoogle Scholar
  19. 19.
    Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRefGoogle Scholar
  20. 20.
    Boige V, Pignon J, Saint-Aubert B et al (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25:18sGoogle Scholar
  21. 21.
    Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210PubMedCrossRefGoogle Scholar
  22. 22.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMedCrossRefGoogle Scholar
  23. 23.
    Regine WF, Abrams RA (2006) Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol 33:S10–S13PubMedCrossRefGoogle Scholar
  24. 24.
    Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMedCrossRefGoogle Scholar
  25. 25.
    Abbruzzese J, Kurzrock R, McConkey D et al (2007) Are there rational novel targets for pancreatic cancer terapeutics? Observation from the MD Anderson Cancer Center SPORE in pancreatic cancer. Eur J Cancer 5:149Google Scholar
  26. 26.
    Li L, Aggarwal BB, Shishodia S et al (2004) Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101:2351–2362PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Massimo Lopez
    • 1
  • Laura Giacinti
    • 2
  • Silvia I.S. Fattoruso
    • 1
  1. 1.Istituto Nazionale Tumori “Regina Elena”RomeItaly
  2. 2.“San Giuseppe” HospitalRomeItaly

Personalised recommendations